a Background: Cytomegalovirus (CMV) is a common HIV-1 copathogen. Since CMV infection is an important contributor to immune activation, the driving force of HIV disease, an anti-CMV strategy might be beneficial to HIV-infected patients. Shin et al. (J Acquir Immune Defic Syndr 2014; 65:251-258) reported that anti-CMV therapy with valganciclovir in coinfected individuals results in a decrease of HIV viral load that is not accompanied by a decrease of immune activation. This suggests an alternative mechanism for HIV inhibition other than suppression of CMV-mediated inflammation.
Introduction
Human cytomegalovirus (CMV) is a b human herpesvirus (HHV) with high prevalence in both the general population ($65%) and in HIV-infected individuals ($90%) [1, 2] . Like herpes simplex virus (HSV)-2 and other sexually transmitted copathogens such as Neisseria gonorrhea, Chlamydia trachomatis, Treponema pallidum, and Trichomonas vaginalis, CMV has been considered a cofactor in HIV transmission [3] [4] [5] [6] [7] [8] . In particular, the compartmentalized reactivation of CMV in genital mucosa has been associated with recruitment of immune cells [9] [10] [11] [12] , local changes in chemokine spectra [13, 14] , and mucosal inflammation that is associated with increased HIV-1 viral loads in cervicovaginal secretion and semen [13, [15] [16] [17] [18] [19] . More recent data have shown that CMV infection may also contribute to systemic immunoactivation in HIV-infected individuals whether they are treated or not. This immunoactivation contributes to the prevalence of cardiovascular disease, cancer, fragility, and general aging [20, 21] . These findings generated interest in evaluating the possible clinical benefits of anti-CMV strategies for prevention of both HIV infection and HIV comorbidities.
Towards this goal, Shin et al. [22] assessed the effect of CMV therapy on HIV genital levels by evaluating the impact of valganciclovir [a valine ester prodrug of ganciclovir (GCV)] on HIV-infected, antiretroviral therapy (ART)-naive men in an open label observational study. Valganciclovir treatment resulted in the reduction not only of CMV but also of HIV-1 viral load in blood and in semen. The decrease in the semen HIV viral load was not associated with immune parameters (activated T cells and inflammatory cytokines), suggesting that the reduced HIV viral load in semen could not be solely explained by the suppression of immune activation but rather by alternative mechanisms, as hypothesized by the authors [22] . Here, we describe such a mechanism: we showed that GCV has a direct suppressive effect on HIV-1 replication in human lymphoid and cervical tissues ex vivo. The molecular mechanism of this suppression involves GCV-triphosphate (GCV-TP), the active form of GCV, being incorporated into the nascent DNA chain by HIV-1 reverse transcriptase and then acting as a delayed chain terminator. All tissues were obtained according to Institutional review board-approved protocols. Tissues were dissected into 2-mm blocks and cultured as described earlier [28] . Tissue inoculations with HIV-1 and CMV were performed as described earlier [29, 30] . GCV (Bedford Laboratories, Bedford, Ohio, USA) was present during the entire period of culture and was replenished with each medium change (every 3 days).
Materials and methods

Tissue culture and viral infection
Cytokines/chemokines quantification Concentrations of 32 cytokines/chemokines were measured in supernatants of tissue cultures using a multiplex bead array assay [31] (See supplementary data for details, http://links.lww.com/QAD/B101).
Viability assay in human lymphoid tissue
Cell viability in human tonsillar tissues treated with GCV (5 or 50 mmol/l) was assessed as [32] (See supplementary data for details, http://links.lww.com/QAD/B101).
Exogenous template reverse transcriptase assay HIV-1 reverse transcriptase was expressed and purified as described previously [33] . T50A (CCAATATTCACC ATCAAGGCTTGACGTGACTTCACTCCACTATA CCACTC) and T50A6 (CCAATATTCACCATCAAG GCTTGATGAAACTTCACTCCACTATACCACTC) were used as templates for DNA synthesis. P1 (GAGTGG TATAGTGGAGTGAA), P1a (GAGTGGTATAGTGG AGTGAAGT), and P1f (GAGTGGTATAGTGGAGTG AAGTTT) were used as primers. We performed synthesis of oligonucleotides containing internal GCV-monophosphate residues enzymatically using HIV-1 reverse transcriptase in a standard primer extension reaction [34] . Samples were subsequently resolved via 12% denaturing PAGE, and the final DNA product was excised and eluted from the gel matrix in 0.5 mol/l ammonium acetate and 0.1% SDS. Full-length DNA synthesis by HIV-1 reverse transcriptase and steady-state kinetics of single nucleotide incorporation by reverse transcriptase were performed as described in the supplementary file, http://links.lww.-com/QAD/B101.
Results
Ganciclovir suppresses C-C chemokine receptor 5 and C-X-C chemokine receptor 4-tropic HIV-1 infection in human tissues ex vivo To test the effect of GCV on HIV replication, we used tonsillar and cervicovaginal tissues, cultured as described earlier [28] . Briefly, 27 human tissue blocks for each experimental condition from each of three donors were infected with a prototypic C-X-C chemokine receptor 4 (CXCR4) or C-C chemokine receptor 5 (CCR5)-tropic variant of HIV, respectively X4 LAI.04 or R5 BaL , and incubated with GCV for 12 days. Culture medium was changed and GCV was replenished every 3 days. Donormatched infected tissues not treated with GCV were used as controls. We found that GCV significantly (P < 0.01) suppressed HIV-1 replication, evaluated as p24 gag accumulation in culture medium. On average, GCV treatment of ex-vivo human tonsils reduced production of p24gag in culture medium from 10 600 AE 4400 pg/ml to 1430 AE 409 pg/ml and in ex-vivo human cervicovaginal tissues from 2057 AE 445 pg/ml to 174 AE 39 pg/ml (n ¼ 3; Fig. 1a and b) . To account for donor-to-donor variability, we normalized these data by calculating the relative suppression of HIV replication in each donor tissue. On average, in tonsils infected with X4 LAI.04 , GCV suppressed replication by 83.9 AE 5.8%, and in cervicovaginal tissues infected with R5 BaL by 90.0 AE 4.03% (n ¼ 3).
Although both cellular viral kinases encoded by endogenous HHVs, which are reactivated during the culture of human tissues ex vivo, are able to phosphorylate nucleotide analogs [30] ; here, we decided to infect tissues with CMV, as GCV is specifically activated by UL97-encoded kinase expressed by CMV. To investigate whether exogenous CMV would confer better anti-HIV activity of GCV, we compared the HIV-inhibitory effect of GCV in tonsillar tissues that we infected with CMV and HIV and in donor-matched controls that were infected with HIV only. We found that the suppression of HIV-1 replication was dose dependent and not statistically different whether we coinfected HIV-infected tissues with CMV or not. The 50% effective concentrations of GCV in tonsillar tissue blocks were, respectively 4.7 mmol/l (95% confidence interval: 0.9-24.9) in HIV-1-singly infected tissues and 5.4 mmol/l (95% confidence interval: 1.5-19.0) in CMV-coinfected tissues (Fig. 1c) .
Ganciclovir suppresses infection of HIV-1 of clades A, B, and C in human tissues ex vivo
We evaluated the susceptibility of three primary isolates to GCV: HIV-197USNG30 of clade C, HIV-196USNN20 of clade A, and HIV-1ME1 of clade B. Primary isolate HIV-196USNN20 has a broad coreceptor utilization, including CCR2B, CCR3, CCR4, CCR5, CXCR4, Bob and Bonzo, whereas HIV-197USNG30 and HIV-1ME1 are exclusively CCR5 tropic. Human lymphoid tissues (27 tissue blocks per experimental condition) were inoculated with each of these three isolates and then treated for the entire culture period with 5 or 50 mmol/l GCV (which is, respectively, the 50% effective concentration and a concentration that completely suppresses X4 LAI.04 replication in this system). We found that GCV suppressed replication of all the three tested primary isolates and this suppression was not significantly different from that of laboratory isolate X4 LAI.04 at both 5 and 50 mmol/l GCV (P > 0.05; Fig. 1d ).
Ganciclovir suppresses replication of drugresistant HIV-1 in human tissues ex vivo First, we investigated the sensitivity of NRTI-resistant virus to GCV (5 and 50 mmol/l) in human tissue ex vivo.
In particular, we evaluated the sensitivity to GCV of a azidothymidine-resistant HIV [35] and two NRTImultidrug-resistant molecular clones (clones 10076-4 and 7303-3). The molecular clones belong to a panel of six prototypical infectious multi-NRTI-resistant HIV-1 molecular clones that carry several prototypical mutations conferring resistance to at least two of the following NRTIs: abacavir, zidovudine, stavudine, zalcitabine, didanosine, tenofovir, and lamivudine [36] . (Fig. 1d) .
Incorporation of ganciclovir triphosphate by HIV-1 reverse transcriptase results in downstream DNA synthesis inhibition
We hypothesized that GCV-TP interferes with the activity of HIV-1 reverse transcriptase and directly suppresses HIV-1 replication. To test this hypothesis, we evaluated the ability of GCV-TP to suppress HIV-1 reverse transcriptase by measuring the polymerizing activity of purified recombinant enzyme using an exogenously added primer-template hybrid (Fig. 2a) .
In particular, we assessed the extension of a GCVmonophosphate-terminated primer using a multiple Multisite DNA synthesis was performed by HIV-1 RT using GCV-MP-chain-terminated primers hybridized to a DNA template (shown in figure) . Pausing sites for DNA synthesis for RT are marked with arrows; increasing concentrations of nucleotide are able to rescue DNA synthesis. The full-length product is marked as 'fl'. Presented is one representative gel of three. (b). Experimental design for steady-state kinetics of single-nucleotide incorporation. a. The primer/template system used for comparing the incorporation of dGTP and GCV-TP used to generate the kinetic constants shown in Table 1 is shown. b. The primer/template sequences used to generate the kinetic constants found in Table 2 nucleotide incorporation assay. Pausing in DNA synthesis was observed at positions n þ 1 and n þ 3 for HIV-1 reverse transcriptase when GCV monophosphate was located at position n. These pausing sites were overcome with increasing concentrations of nucleotides, suggesting that either compromised nucleotide binding following these pausing sites or hybrid dissociation was caused by GCV monophosphate that was located in the primer strand.
Kinetic comparison of ganciclovir triphosphate and dGTP incorporation for HIV-1 reverse transcriptase To probe the structural determinants governing the efficiency of GCV-TP incorporation, we employed a steady-state kinetic approach to compare GCV-TP incorporation with that of the natural dGTP substrate (Table 1) . For reverse transcriptase, the rate of GCV-TP incorporation (denoted by k cat ) was similar to that for the natural dGTP substrate; however, HIV-1 reverse transcriptase displayed marked increases in K m values for GCV-TP compared with dGTP (HIV-1 reverse transcriptase: 0.058 mmol/l for dGTP and 4.4 mmol/l for GCV-TP) [37] .
Difference in efficiency of nucleotide incorporation downstream of ganciclovir monophosphate in the primer strand
In an effort to analyze the pattern of inhibition by GCV-TP, a steady-state kinetic analysis of single nucleotide incorporation by HIV reverse transcriptase was conducted; the positions for nucleotide incorporation selected were those immediately following the pausing sites seen in the full-length DNA synthesis experiment for HIV-1 reverse transcriptase (Fig. 2b) , namely positions n þ 2 and n þ 4. The kinetic analysis for these two primer systems with internal GCV-monophosphate residues was compared with the control primer system having the natural dGMP located at position n. The results (Table 2 ) point to a distinct mechanism of inhibition for HIV-1 reverse transcriptase. Although nucleotide incorporation is 27-fold less efficient at position n þ 2 when GCV monophosphate is located at position n than the control with dGMP at position n, the efficiency of nucleotide incorporation is over 1000-fold less efficient at position n þ 4 when GCV monophosphate is found at position n, as compared with the control.
Ganciclovir does not decrease inflammation/ activation in human tissues ex vivo
Although the data above indicates that GCV acts directly on HIV, we investigated alternative potential mechanisms of such an inhibition: the decrease of general inflammation of the tissue and the decrease of the activation status of tonsillar cells, in particular of CD4 þ T cells. We addressed these two possibilities in two different sets of experiments.
First, we measured the levels of 32 cytokines/chemokines in the supernatants of human tissues treated or not with GCV. Tissues were treated with 5 mmol/l GCV (50% The selectivity of nucleotide incorporation for a position was determined by dividing the efficiency of nucleotide incorporation for dCTP incorporation in the absence of GCV-MP in the primer by the efficiency of nucleotide incorporation for dCTP incorporation in the presence of GCV-MP in the primer. effective concentrations of X4 LAI.04 ) or 50 mmol/l GCV (10-fold higher than 50% effective concentrations). Among the 22 cytokines/chemokines detectable in tonsillar tissue cultures, none were significantly different in tissues treated with GCV (whether tissues were treated with 5 mmol/l or 50 mmol/ GCV) compared to their counterparts in untreated tissue cultures (Table 3 ).
AIDS 2017, Vol 31 No 11
In the second set of experiments, we specifically investigated whether GCV affected the viability of tissue cells, in particular the viability of HIV target cells (CD4 þ T cells expressing CXCR4 or CCR5) including activated T cells (CD25 þ or CD38 þ ; Fig. 1d ). After 12 days in culture, we isolated cells from tissue blocks treated with 5 or 50 mmol/l GCV and from donor-matched untreated tissue and stained them for CD3, CD4
þ , CD8 À , CXCR4, CCR5, CD25, and CD38. We evaluated the cytopathicity of GCV by comparing the number of cells in GCV-treated tissues with those in matched untreated tissues using a novocyte flow cytometer, which allowed us to acquire a similar volume for each experimental condition. To account for size differences in tissue blocks, we normalized the data by the weight of the tissues. Figure 1e showed that GCV, even at the concentration of 50 mmol/l, did not deplete any cell subset, including activated CD4 þ T cells that are primary targets for HIV.
Discussion
It is commonly accepted that persistent immune activation is a driving force of HIV disease. In HIV-1-infected individuals, CMV prevalence is around 90%, and a growing body of evidence suggests that asymptomatic replication of CMV, a member of the HHV family, may be an important contributor to this persistent immune activation (reviewed in [8, 21] ) accelerating the development of HIV-triggered immunological abnormalities [8, [38] [39] [40] [41] . In particular, CMV shedding in the genital tract has been associated with increased T-cell immune activation and proliferation in peripheral blood [9] [10] [11] 40] , higher HIV-1 shedding in semen [13, [15] [16] [17] 19] , and higher risk of HIV-1 transmission [3, 6, 7] . Both CMV and HIV are associated with inflammationrelated morbidities [21] . Several studies have suggested that both direct and indirect interactions between CMV and HIV could influence their replication and the resulting disease pathogenesis. Freeman et al. [21] reported on several of such interactions making the contribution of CMV to HIV pathogenesis and vice versa difficult to tease apart.
ART has affected the course of HIV infection in a revolutionary way, dramatically decreasing the mortality of Ganciclovir inhibits HIV-1 Vanpouille et al. 1525 Table 3 . Cytokine/chemokine expression in human tissue ex vivo treated or not with ganciclovir. Levels of 32 cytokines/chemokines present in the supernatant of tonsillar tissue cultures untreated or treated with 5 or 50 mmol/l GCV were measured using a multiplex bead assay as described in. Ten cytokines/chemokines were not detected, whereas 22 were detected but not statistically different in tissues treated with GCV versus untreated tissues control. For each cytokine and each experimental condition (untreated control, GCV 5 and GCV 50 mmol/l), cumulative production over a 12-day period of culture was evaluated and results were expressed as fractions of control. Statistical significance was assessed by Wilcoxon signed-rank test. P < 0.05 was considered to be significant. Presented are means AE SEM from experiments with five different tissue donors. GCV, ganciclovir; GM-CSF, granulocyte-macrophage-colony-stimulating factor; GRO, growth regulated oncogene; IFN, interferon; IP, IFN-inducible-protein; ITAC, IFN-inducible T-cell a chemoattractant; MCP, monocyte-chemotacticprotein; MIG, monokine induced by gamma interferon; RANTES, regulated-on-activation-normally-T-cell-expressed-and-secreted; TNF, tumor necrosis receptor. The method of detection of cytokines/chemokines was based on [31] .
HIV-1-infected individuals, and reducing complications associated with opportunistic infections. However, even with sustained suppression of HIV replication, abnormal immune activation persists in most of these individuals. This immune activation is associated with subsequent morbidity and earlier mortality [42] . It has been suggested that CMV contributes to immune activation even when ART has suppressed HIV replication [10, 19, [43] [44] [45] [46] .
These observations suggested that treating asymptomatic CMV coinfection may be beneficial by suppressing general T-cell activation, and ultimately decreasing HIV-1 viral load, as well as delaying HIV disease progression [10, 22] . In this context, Shin et al. [22] investigated the effect of anti-CMV therapy using valganciclovir on immune activation and HIV-1 viral load in semen. They found that GCV did indeed reduce HIV-1 viral load. However, this reduction was surprisingly not associated with decreases in T-cell activation and in production of inflammatory cytokines.
On the basis of GCV-mediated reduction of HIV-1 genital viral load in the absence of significant genital changes in immunoactivation, we hypothesized along with Shin et al. [22] that GCV has a direct effect on HIV replication provided it is phosphorylated by cellular or HHV TK.
Here, we tested this hypothesis in human tissues ex vivo. These are adequate models for preclinical drug testing, as they support productive HIV infection without exogenous activation and stimulation. Moreover, ex vivo tissues retain cytoarchitecture as well as the pattern of expression of key cell-surface molecules relevant to HIV infection [28] . First, we tested the sensitivity of two laboratory isolates of HIV-1, of CXCR4-tropicX4 LAI.04 and of CCR5-tropic R5 BaL . We demonstrated that GCV inhibited HIV-1 in both lymphoid and cervicovaginal tissues ex vivo and that GCV inhibited both X4 and R5 HIV-1. HIV-1 inhibition was not limited to laboratory isolates as three HIV-1 primary isolates of different subtypes (A, B, and C) were also suppressed by GCV. Also, GCV sensitivity was not limited to the wild-type HIV-1 as NRTI, nNRTI, fusion inhibitor, and protease inhibitor-resistant viruses were all sensitive to GCV.
To investigate whether HIV inhibition by GCV was the result of a direct inhibition on the virus itself rather than the result of a GCV-mediated decrease of inflammation of the tissue, we measured the levels of 32 cytokines/ chemokines (including but not limited to inflammatory cytokines) in the supernatants of tonsillar tissues treated or not with GCV. No significant difference in any levels of cytokines/chemokines was found between treated and untreated tissues. Neither did we find that GCV affected the viability or the number of tonsillar cells, in particular of CD4 þ T cells, which are the primary target cells for HIV infection. Thus, it seems that GCV inhibited HIV-1 replication by directly affecting the virus and not by decreasing inflammation or activation of the tissue.
GCV is a synthetic purine nucleoside analogue of guanine and also has to undergo triphosphorylation to become active, with the initial monophosphorylation catalyzed more efficiently by HHV-encoded kinase than by cellular kinases. HHVs seem to be necessary to inhibit HIV-1, as GCV did not inhibit HIV-1 in MT-4 cell cultures (data not shown), which are free of endogenous HHVs [30] . Moreover, we showed here that the 50% effective concentrations of GCV for HIV-1 was approximately 5 mmol/l, whether human tissues were exogenously coinfected with CMV or not. Thus, it seems that kinases expressed by endogenous HHVs activate GCV by adding the first phosphate. HHV-6 U69-encoded kinase is one such enzyme that has been shown to phosphorylate ganciclovir [47] .
Both the multisite incorporation assay and the steadystate kinetic analysis suggest that GCV monophosphate inhibits HIV-1 reverse transcriptase by acting as a delayed chain terminator. It is possible that the inhibitor's interaction with reverse transcriptase is more strongly compromised by the lack of the sugar ring stacking with the enzyme that is seen with the natural dGTP substrate.
Using a steady-state kinetic approach, we found that the major mechanism of inhibition of HIV-1 reverse transcriptase by GCV was through a block in nucleotide incorporation at position nþ4, as the efficiency of nucleotide incorporation was over 1000-fold less efficient at position nþ4 when GCV-monophosphate is found at position n. In comparison, the efficiency of nucleotide incorporation was over 27-fold less efficient at position nþ2 when GCV monophosphate was found at position n.
GCV is not the first delayed chain terminator to be described, as entecavir has been shown to block DNA synthesis through inhibition at positions n þ 1 (minor) and n þ 4 (major) in HIV-1 reverse transcriptase [48] . However, both the chemical structures and the mechanisms of action of GCV and entecavir are different, indicating that diverse mechanisms of delayed chain termination can be obtained from chemical modification of the inhibitor.
The effect of GCVon HIV viral load in CMV-coinfected tissues resembles that of acyclovir (ACV) in HSV-2-coinfected individuals. As with the inhibition of HIV by GCV, the inhibition of HIV by ACV was thought to proceed exclusively via an indirect mechanism. Indeed, the effect of ACV on HIV viral load was initially attributed to the suppression of HSV-2 replication followed by the suppression of HSV-2-triggered inflammation [49, 50] . However, we and others [30, 51, 52] have found that ACValso has a direct effect on HIV-1 after the drug is phosphorylated by HHV. The direct inhibitory effect of ACV on HIV viral load observed ex vivo was recently confirmed in vivo in a double-blind crossover clinical trial [53] . In this trial, we showed that valacyclovir (a prodrug of ACV) suppresses HIV-1 viral load in HIV-1-infected HSV-2 seronegative persons, proving that the effects of valacyclovir on HIV-1 are consistent with a direct effect of ACV on HIV-1 replication [53] .
As with what we previously described for ACV/valACV, here, we found that GCV inhibited HIV in human tissues ex vivo but not in cell lines. Indeed, no anti-HIV effect of GCV was observed here in MT-4 cell lines or in H9 cells as reported by Medina et al. [54] . The anti HIV activity of GCV may be directly related to endogenous HHVs present in tissues [30] but not in cell lines [30] . Indeed, HHVs are ubiquitous in the tonsillar tissues. Earlier we found that 96% of tonsillar tissues (received from the same hospital as in the current study) were positive for one or several HHVs. In particular, real-time PCR analysis revealed CMV in 15% of tissues; EBV in 52%; HHV-7 in 89%; and HHV-6 in 96% of tissues.
The anti-HIV activity of the GCV occurs at clinically relevant concentrations. Indeed, although GCV penetration efficiency and drug clearance were unknown for ex-vivo tissues, the calculated 50% effective concentrations of 4.7 mmol/l is in the range of what has been reported in vivo [55] . For a dose of 900 mg of oral valganciclovir per day, the maximum mean plasma concentration is 26.3 mmol/l with a mean Area under the curve 0-24 of 51.2 mgh/ml, and plasmatic concentrations remain higher than 4.9 mmol/l for the first 15 h after drug administration [55] .
In conclusion, our results suggest that an anti-CMV strategy using valganciclovir in HIV-1-infected individuals may reduce HIV-1 viral load directly by inhibiting HIV-1 reverse transcriptase. Given the potential impact of CMV in immune activation and the potential role of CMV in various human pathologies, in particular in cardiovascular disease, T-cell senescence, and aging, strategies to reduce CMV replication in HIV-infected individuals may turn out to be beneficial.
